Literature DB >> 24690158

Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging study.

Jong Woo Lee1, Andrew D Norden2, Keith L Ligon3, Alexandra J Golby4, Rameen Beroukhim2, John Quackenbush5, William Wells6, Kristen Oelschlager7, Derek Maetzold7, Patrick Y Wen2.   

Abstract

Tumor associated seizures (TAS) are common and cause significant morbidity. Both imaging and gene expression features play significant roles in determining TAS, with strong interactions between them. We describe gene expression imaging tools which allow mapping of brain regions where gene expression has significant influence on TAS, and apply these methods to study 77 patients who underwent surgical evaluation for supratentorial glioblastomas. Tumor size and location were measured from MRI scans. A 9-set gene expression profile predicting long-term survivors was obtained from RNA derived from formalin-fixed paraffin embedded tissue. A total of 32 patients (42%) experienced preoperative TAS. Tumor volume was smaller (31.1 vs. 58.8 cubic cm, p<0.001) and there was a trend toward median survival being higher (48.4 vs. 32.7 months, p=0.055) in patients with TAS. Although the expression of only OLIG2 was significantly lower in patients with TAS in a groupwise analysis, gene expression imaging analysis revealed regions with significantly lower expression of OLIG2 and RTN1 in patients with TAS. Gene expression imaging is a powerful technique that demonstrates that the influence of gene expression on TAS is highly region specific. Regional variability should be evaluated with any genomic or molecular markers of solid brain lesions.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain tumor; Gene expression; Imaging; Seizure

Mesh:

Substances:

Year:  2014        PMID: 24690158      PMCID: PMC4076930          DOI: 10.1016/j.eplepsyres.2014.02.021

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  46 in total

1.  Nonparametric permutation tests for functional neuroimaging: a primer with examples.

Authors:  Thomas E Nichols; Andrew P Holmes
Journal:  Hum Brain Mapp       Date:  2002-01       Impact factor: 5.038

Review 2.  Characteristics and treatment of seizures in patients with high-grade glioma: a review.

Authors:  Dario J Englot; Mitchel S Berger; Edward F Chang; Paul A Garcia
Journal:  Neurosurg Clin N Am       Date:  2012-04       Impact factor: 2.509

3.  Epileptic seizures during follow-up of patients treated for primary brain tumors.

Authors:  Jerzy Hildebrand; Cristel Lecaille; Joëlle Perennes; Jean-Yves Delattre
Journal:  Neurology       Date:  2005-07-26       Impact factor: 9.910

4.  OLIG2 as a specific marker of oligodendroglial tumour cells.

Authors:  Y Marie; M Sanson; K Mokhtari; P Leuraud; M Kujas; J Y Delattre; J Poirier; B Zalc; K Hoang-Xuan
Journal:  Lancet       Date:  2001-07-28       Impact factor: 79.321

5.  Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome.

Authors:  Yongzhi Wang; Shouwei Li; Lingchao Chen; Gan You; Zhaoshi Bao; Wei Yan; Zhendong Shi; Yin Chen; Kun Yao; Wei Zhang; Chunsheng Kang; Tao Jiang
Journal:  Neuro Oncol       Date:  2012-02-10       Impact factor: 12.300

Review 6.  Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments.

Authors:  Roberta Rudà; Lorenzo Bello; Hugues Duffau; Riccardo Soffietti
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

7.  Imaging features of invasion and preoperative and postoperative tumor burden in previously untreated glioblastoma: Correlation with survival.

Authors:  Rohan Ramakrishna; Jason Barber; Greg Kennedy; Adnan Rizvi; Robert Goodkin; Richard H Winn; George A Ojemann; Mitchel S Berger; Alexander M Spence; Robert C Rostomily
Journal:  Surg Neurol Int       Date:  2010-08-10

8.  Increased expression of aquaporin-1 in the anterior temporal neocortex of patients with intractable epilepsy.

Authors:  Shengnian Zhou; Xian Sun; Liqing Liu; Xuefeng Wang; Kunbin Liu
Journal:  Neurol Res       Date:  2008-05       Impact factor: 2.448

9.  Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review.

Authors:  Laura M Lynam; Mark K Lyons; Joseph F Drazkowski; Joseph I Sirven; Katherine H Noe; Richard S Zimmerman; James A Wilkens
Journal:  Clin Neurol Neurosurg       Date:  2007-06-29       Impact factor: 1.876

10.  Expression and immunolocalization of Gpnmb, a glioma-associated glycoprotein, in normal and inflamed central nervous systems of adult rats.

Authors:  Jian-Jun Huang; Wen-Jie Ma; Shigeru Yokoyama
Journal:  Brain Behav       Date:  2012-03       Impact factor: 2.708

View more
  5 in total

1.  What is New in the Management of Epilepsy in Gliomas?

Authors:  Roberta Rudà; Riccardo Soffietti
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

2.  New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma.

Authors:  Tunc F Ersoy; Vera C Keil; Dariusch R Hadizadeh; Gerrit H Gielen; Rolf Fimmers; Andreas Waha; Barbara Heidenreich; Rajiv Kumar; Hans H Schild; Matthias Simon
Journal:  Neuroradiology       Date:  2017-09-11       Impact factor: 2.804

Review 3.  Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy.

Authors:  Terri S Armstrong; Robin Grant; Mark R Gilbert; Jong Woo Lee; Andrew D Norden
Journal:  Neuro Oncol       Date:  2015-11-02       Impact factor: 12.300

4.  Epilepsy in Adults with Supratentorial Glioblastoma: Incidence and Influence Factors and Prophylaxis in 184 Patients.

Authors:  Shuli Liang; Junchen Zhang; Shaohui Zhang; Xiangping Fu
Journal:  PLoS One       Date:  2016-07-20       Impact factor: 3.240

5.  Antiepileptic drug treatment after an unprovoked first seizure: A decision analysis.

Authors:  Erik L Bao; Ling-Ya Chao; Peiyun Ni; Lidia M V R Moura; Andrew J Cole; Sydney S Cash; Daniel B Hoch; Matt T Bianchi; M Brandon Westover
Journal:  Neurology       Date:  2018-09-12       Impact factor: 11.800

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.